Prognostic role of survivin in patients with glioma

Zhang, Sunfu; Zhang, Changwei; Song, Yanlin; Zhang, Jing; Xu, Jianguo

doi:10.1097/md.0000000000010571

Cited by 34 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the main factors that affect OS in glioma patients were tumor characteristics, [ 26 ] whereas they were similar between the 2 groups, which might weaken the effect of RTBC program.…”

Section: Discussionmentioning

confidence: 99%

Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors

Zhao

2021

Medicine

View full text Add to dashboard Cite

This study aimed to evaluate the effect of reminiscence therapy-based care (RTBC) program on anxiety, depression, patients satisfaction, and survival benefit in glioma patients after tumor resection. A total of 150 eligible glioma patients were randomized into the RTBC group (N = 75, receiving RTBC) and the control care (CC) group (N = 75, receiving CC). Interventions were performed twice a month for 12 months. Anxiety was evaluated by Hospital Anxiety and Depression Scale (HADS) for anxiety score and Zung self-rating anxiety scale (SAS) score; meanwhile, depression was evaluated by HADS for depression score and Zung self-rating depression scale (SDS) score; additionally, patients satisfaction was scored. A 36-month follow-up was performed, and accumulating overall survival (OS) were calculated. Both anxiety level and depression level were reduced in the RTBC group compared with the CC group at month 9 and month 12 (all P < .05); meanwhile, the proportion of anxious patients and depressed patients were decreased in the RTBC group compared with the CC group at month 12 (all P < .05). Moreover, patients satisfaction scores were increased in the RTBC group compared to the CC group at month 6, month 9, and month 12 (all P < .05). Additionally, accumulating OS showed an increasing tendency in the RTBC group compared to the CC group, but no statistical significance was observed ( P = .186). RTBC program ameliorates anxiety, depression, and promotes patients satisfaction in glioma patients after tumor resection.

show abstract

“…the main factors that affect OS in glioma patients were tumor characteristics, [ 26 ] whereas they were similar between the 2 groups, which might weaken the effect of RTBC program.…”

Section: Discussionmentioning

confidence: 99%

Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors

Zhao

2021

Medicine

View full text Add to dashboard Cite

show abstract

“…We found high levels of survivin expression in U251MG cells compared to normal astrocytes. It was suggested that higher survivin expression was associated with worse overall survival in patients with glioma [32]. Recently, survivin has attracted attention as a therapeutic target molecule for glioma [33][34][35].…”

Section: Discussionmentioning

confidence: 99%

Anticancer Activity of Amb4269951, a Choline Transporter-Like Protein 1 Inhibitor, in Human Glioma Cells

et al. 2020

View full text Add to dashboard Cite

Choline transporter-like protein 1 (CTL1) is highly expressed in glioma cells, and inhibition of CTL1 function induces apoptotic cell death. Therefore, CTL1 is a potential target molecule for glioma therapy. Here, we investigated the therapeutic mechanism underlying the antitumor effects of Amb4269951, a recently discovered novel CTL1 inhibitor, in the human glioma cell line U251MG, and evaluated its in vivo effects in a mouse xenograft model. Amb4269951 inhibited choline uptake and cell viability and increased caspase-3/7 activity. CTL1-mediated choline uptake is associated with cell viability, and the functional inhibition of CTL1 by Amb4269951 may promote apoptotic cell death via ceramide-induced suppression of the expression of survivin, an apoptotic inhibitory factor. Finally, Amb4269951 demonstrated an antitumor effect in a mice xenograft model by significantly inhibiting tumor growth without any weight loss. Amb4269951 is the lead compound in the treatment of glioma and exhibits a novel therapeutic mechanism. These results may lead to the development of novel anticancer drugs targeting the choline transporter CTL1, which has a different mechanism of action than conventional anticancer drugs against gliomas.

show abstract

“…Survivin localizes to the mitotic spindle and participates in regulating mitosis. In addition to GE cancers, it is highly expressed in various other malignancies and is associated with inferior outcomes including a shorter survival period (13)(14)(15). CENPF gene encodes centromere protein F that associates with the centromere-kinetochore complex.…”

Section: Discussionmentioning

confidence: 99%

Characterization of Leading Dysregulated Plasma-Proteome Associated Genes in Patients with Gastro-Esophageal Cancers.

Vizeacoumar¹,

Dwernychuk²,

Zaidi³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Gastro-esophageal cancers are one of the major causes of cancer-related death in the world. There is a need for novel biomarkers in the management of gastro-esophageal cancers to identify new therapeutic targets and to yield predictive response to the available therapies. Our study aims to identify leading genes that are dysregulated (upregulated or downregulated) in patients with gastro-esophageal cancers.Methods: We examined gene expression data for those genes whose protein products can be detected in the plasma in 600 independent tumor samples and 46 matching normal tissue samples using the Cancer Genome Atlas (TCGA) to identify leading genes that are dysregulated in patients with gastro-esophageal cancers. Non-parametric Mann-Whitney-U test was used to evaluate differential expression of genes using a cut-off of P< 0.05.Results: The comparison between tumors sample and healthy tissue showed BIRC5 (p=2.61 E-08), APOC2 (p=3.23E-08), CENPF (p=4.38E-08), STMN1 (p=5.74E-08), and HNRPC (p=8.21E-08) were the leading genes significantly overexpressed in esophageal cancer whereas CST1 (p=3.97 E-21), INHBA (p=9.22E-20), ACAN (p=1.08E-19), HSP90AB1 (p=2.62E-19), and HSPD1 (p=3.91E-19) were the leading genes that were overexpressed in stomach cancer. Conversely, C16orf89 (9.78E-08), AR (1.01E-07), CKB (1.17E-07), ADH1B (1.79E-07), and NCAM1 (2.15E-07) were the leading gene that were significantly downregulated in esophageal cancer whereas GPX3 (1.65E-19), CLEC3B (5.70E-19), CFD (5.68E-18), GSN (4.5IE-17), and CCL14 (1.12E-16) were significantly downregulated in stomach cancer. Furthermore, Stage-based examination showed stage-specific differential expression of various genes as well as stage-wise increasing or decreasing up-regulation or down-regulation of selected genes, respectively. Conclusions: The present study identified leading upregulated and downregulated genes in gastro-esophageal cancers that can be detected in the plasma proteome. These genes have potential to become diagnostic and therapeutic biomarkers for early detection of cancer, recurrence following surgery and for development of targeted-treatment.

show abstract

Prognostic role of survivin in patients with glioma

Cited by 34 publications

References 41 publications

Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors

Reminiscence therapy-based care program for reducing anxiety and depression in glioma survivors

Anticancer Activity of Amb4269951, a Choline Transporter-Like Protein 1 Inhibitor, in Human Glioma Cells

Characterization of Leading Dysregulated Plasma-Proteome Associated Genes in Patients with Gastro-Esophageal Cancers.

Contact Info

Product

Resources

About